An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis
| Autor: | Sidra Saleem, Fatima Anwer, Muniba Fayyaz, Arsalan Anwar, Faria Anwar |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty medicine.drug_class relapsing remitting multiple sclerosis Inflammation 030204 cardiovascular system & hematology Monoclonal antibody Allergy/Immunology Pathogenesis 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Immune system Internal medicine Pathology therapeutics medicine Glatiramer acetate business.industry Multiple sclerosis General Engineering deep brain lesions autoimmune medicine.disease Siponimod Neurology chemistry demyelination Stem cell medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Cureus |
| ISSN: | 2168-8184 |
| Popis: | Multiple sclerosis (MS) is a chronic disorder of the central nervous system (CNS). MS affects 2.1 million individuals every year and is also considered a major cause of economic health burden around the world. Genetics and environmental factors both play a role in the pathogenesis of MS by activating the immune response and causing inflammation. Patients with MS can have various clinical courses, but the most common pattern seen is relapsing-remitting multiple sclerosis (RRMS). Multiple therapeutic options have been studied to prevent RRMS patients from frequent relapses. The oldest and most frequently used medication for MS is interferon beta, either used alone or as add-on therapy with other drugs. Newer treatment options that have been recently approved to control MS symptoms and suppress the inflammation are glatiramer acetate and siponimod. Infusion therapies consisting of monoclonal antibodies and immunosuppressive drugs have also been studied in the recent past. Some trials have been conducted on the use of stem cells for RRMS patients. We have briefly discussed all treatment options and the response of RRMS patients in multiple trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|